Breast Cancer – Current Treatment – Detailed, Expanded Analysis: Treatment Sequencing (US)
KEY BENEFITS AND USES
- Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
- Drill down into physicians’ treatment sequences and understand whom to position against or how to defend share.
- Identify untapped treatment scenarios and key competitors to aid trial design.
- Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
- Discover untapped populations to expand product share and drive strategic decisions.
QUESTIONS ANSWERED
- Where is my product positioned versus competitors in the treatment journey?
- What are physicians’ most frequent treatment sequences? Who is benefiting, and how can I defend my asset’s share and position?
- What are the market-relevant treatment scenarios according to oncology experts?
- Where are the untapped business opportunities on which I can capitalize?
- How can I optimize trial design and ensure a competitive edge for my pipeline asset?
GEOGRAPHY
United States.
PRIMARY MARKET RESEARCH
Survey of 100 U.S. medical oncologists.
PRODUCT DESCRIPTION
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and Clarivate oncology experts’ assumptions.
Table of contents
- Breast Cancer - Current Treatment - Detailed, Expanded Analysis: Treatment Sequencing (US)
- Treatment Sequencing | Breast Cancer | US | June 2023
Thomas Pataillot-Meakin, M.Sc., Ph.D., Healthcare Research & Data Analyst, Oncology.
Dr. Pataillot-Meakin has several years of experience in cancer research. Prior to joining Clarivate, he worked in research laboratories developing immunotherapies for neuroblastoma and optimizing and integrating next-generation sequencing into the National Health Service. As a Ph.D. candidate, he studied the use of circulating DNA as a predictive biomarker for prostate and breast cancer. In addition to his Ph.D. from Imperial College London, Dr. Pataillot-Meakin holds a master of science degree in cancer from University College London and a bachelor of science degree in natural sciences, with a major in pharmacology, from the University of Bath.